Novo Nordisk's upcoming weight loss drugs could struggle to stand out among an increasingly competitive field. Investors should be careful not to assume anything. The pharmaceutical industry is ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Reuters reports that online weight loss company Noom will sell low-dose versions of Novo Nordisk's Wegovy. Compounding pharmacies like Noom have struggled to figure out how to sell GLP-1 weight ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

LONDON, May 16 (Reuters) - Wegovy-maker Novo Nordisk (NOVOb.CO), opens new tab said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover ...

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...